In the process of screening for squalene synthase inhibitors from microbial fermentation products we have isolated a novel compound, named schizostatin (Fig. 1) , from the culture broth of the mushroom, Schizophyllum communeSANK17785. Schizostatin inhibited rat liver microsomal squalene synthase dose dependently and the IC50 value was 0.84/^m. The inhibition was competitive with respect to farnesylpyrophosphate with a Ki value of 0.45 jllm.
High levels of cholesterol in blood are considered to be one of the most important risk factors for atherosclerosis and coronary heart diseases, and lowering elevated serum cholesterol levels is a precautionary measure against these diseases.
De novo cholesterol biosynthesis inhibitors, such as pravastatin1}, an inhibitor of reductase, are effective cholesterol lowering agents. The isoprenoid pathway produces not only sterols but also 
Preparation of Rat Liver Microsomes
Weused rat liver microsomes as the enzymesource for the SQSassay. Pravastatin sodium was administered orally to 6-week old male Wistar Imamichi rats (n=5) at a dose of 500mg/kg/day for 6days in order to elevate SQS activity. Microsomes were prepared from the livers of the rats.
Preparation of Radio Active FPP
We used [4-14C] was 5%. After incubation at 37°C for 20minutes, the reaction was terminated by the addition of 100/d 40% KOH-95% EtOH, 1 : 1 (v/v), and saponified at 65°C for 30minutes. Then the mixture was cooled and extracted with 2ml ofhexane using a vortex mixer. One ml of the resultant hexane layer was added to 10 ml of scintillation fluid and radioactivity was determined through liquid scintillation counting. This assay method was used for the determination of the inhibitory activities of the compounds.
Assay Method 2
This assay method was a modification of that ofTait1 1} and was used for multi-screening.
Assays were conducted in a total volume of 50 jA in the wells ofmicrotiter plates. The composition of the reaction mixture was the same as in method 1. 
Fermentation
Schizostatin was produced by Schizophyllum commune SANK 17785 in two 30-liter jar fermentors. Fig. 3 shows the data from a 30-liter fermentation and gives information regarding growth of mycelia, concentration of glycerol, pH and the production of schizostatin. Production of schizostatin began at day 2, and productivity continued to increase after reaching stationary phase. The maximum production was observed at day 5. The fermentation was terminated at day 6 and the à": Schizostatin Og/ml), o: pH, a: glycerol (%), å¡: P.C.V.
(ml/10ml).
yield of schizostatin was 447 fig/ml. Isolation and Purification The purification procedure of schizostatin is outlined in Fig. 4 . The fermentation broth (30 liters) was filtered with celite, and the mycelial cake (4kg) was extracted twice with 30liters of 80% acetone. The acetone was evaporated in vacuo and the residue was added to the filtrate (30liters). This mixture was adjusted to pH 3.5 with 6n HC1 and then extracted twice with 50liters of EtOAc. The combined organic layer was extracted with a 2% NaHCO3solution. The combined water layer was adjusted to pH 3.5 with cone HC1 and then extracted twice with 50liters of EtOAc. The combined organic layer was washed with saturated NaCl solution, dehydrated with Na2SO4and concentrated in vacuo to give 66g of an oily substance. The oily substance was purified by preparative HPLC in 1 1 g aliquots dissolved in-100ml CH3CN. The preparative reverse phase HPLC of the 6 aliquots was performed on a YMC-packC-18 column (10cm x 50cm, Kurita Industries) using 1.0% triethylamine phosphoric acid buffer (pH 3. major peaks were collected at maximumpurity. Each was then reinjected into the column and recollected. The combined 9.5-liter of active fraction was concentrated in vacuo and then extracted with 15liters of EtOAc. The combined organic solvent layer was washed with saturated NaCl solution, dehydrated with Na2SO4 and concentrated in vacuo to yield 9.5 g of schizostatin.
Physico Schizostatin, in a concentration range from 0.01 /xm to IOO jUM, inhibited rat liver microsomal squalene synthase dose dependency. The IC50 value was 0.84paA (Fig. 5) .
In the experiments shown in Table 2 , squalene synthase was preincubated with various concentrations of schizostatin at 37°C for 30minutes, and the concentrations of schizostatin were reduced to one-tenth for enzymeassay. With or without preincubation the inhibition % of SQS by schizostatin was almost the same, indicating that the (Waters) 65%CH3CN-H2Ocontaining 0.3%triethylamine-phosphoric acid buffer (pH3.2) *: Triethylamine phosphate buffer (0.5%, pH 3.2). Enzymeassay was carried out as described in "Materials and Methods",except that the enzymewaspreincubated with various concentrations of schizostatin at 37°Cfor 30 minutes,andthe concentrationsof schizostatin werethen reduced to one-tenth of the preincubated level.
inhibition pattern was completely reversible. From kinetic observations, the inhibition was competitive with respect to farnesylpyrophosphate with a Ki value of 0.45[im (Fig. 6) . The calculated Km value for FPP was 8.6fiM. We synthesized the Z-isomer of schizostatin7'8) and determined its SQS inhibitory activity at the IC50 value of 12/im. It was 15 times less potent than schizostatin ( Table 4) .
Inhibition of Cholesterol Synthesis in Freshly Isolated
Rat Hepatocytes Schizostatin was shownto inhibit the incorporation of [14C]-acetate into cholesterol in freshly isolated rat hepatocytes.
Schizostatin gave a dose-dependent decrease in cholesterol synthesis with an IC50 value of 1.2fM (Fig. 7) .
The enzyme assay was carried out as described in "Materials and Methods", except that the concentration of the substrate was varied as indicated. The analysis was performed under the condition that the enzyme reaction was a linear function of time. The points in the reciprocal plots are the experimentally determined values, while the lines are calculated from the fits of these data to the rate equation for competitive inhibition. The concentration of schizostatin in this experiment was 0 (#), 1.25 (a) and 2.5/im (b). 
Inhibition of Hepatic Sterol Synthesis in Mice by

Schizostatin
Schizostatin was shown to inhibit hepatic cholesterol synthesis in mice with an ED50 value of about 30mg/kg (Table  3) .
Farnesyl Protein Transferase (FPTase)
Inhibition of FPTase from yeast was not observed at the concentration of 300/iM of schizostatin. But the Z-isomer was observed to inhibit it 30% at the concentration of 300im (Table 4) .
Antimicrobial Activities Schizostatin showed no in vitro antimicrobial activity hibitors4'6*. Schizostatin is also expected to have in vivo cholesterol lowering effects. Fromthe comparative study of schizostatin and its Z-isomer (Table 4) , the^-isomer schizostatin is a more selective SQSinhibitor than the Z-isomer. It is reported that chaetomellic acids A and B14), which have a Z-isomer configuration of dicarboxylic acid moieties, have potent inhibitory activity against FPTase but have weak or no inhibitory activity against SQSat the concentration of 150/im. It is interesting that the is-isomer configuration is suitable for the inhibition ofSQS, while on the other hand, the Z-isomer configuration is good for the inhibition of FPTase. 
